AlloRx Stem Cell therapy / Vitro Biopharma - LARVOL DELTA

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R) (BioSpace) - "Vitro Diagnostics, Inc....announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®. This patient was admitted to an emergency room with classic COVID-19 symptoms in late April and had several comorbidities prior to admission....Following the treatment with AlloRx Stem Cells®, the patient experienced resolution of multiple organ failure, recovery from coma, and restoration of neurological, pulmonary, liver and renal function....This study was authorized by the FDA through an Investigational Drug Application (eIND) for emergency use under expanded access....The results of this case support the further study of AlloRx Stem Cell® Therapy for COVID-19 patients..."

Clinical data • Cytokine storm • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease

Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter (Yahoo Finance) - "...Vitro submitted a Phase I IND application to the FDA...to assess safety of AlloRx Stem Cells® in the treatment of COVID-19 patients in the US....The FDA has thus far authorized three separate EUA applications for compassionate use of AlloRx Stem Cells® in COVID-19 patients....Data obtained from these studies corroborates our studies of safety and efficacy. Mesenchymal Stem Cells ('MSCs') block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects."

Clinical data • Cytokine storm • IND • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease